Tonix Pharmaceuticals TNX-102 SL Fibromyalgia 2024

Loading viewer...

conference

Format: PDF conference

Tonix Pharmaceuticals presented its clinical-stage fibromyalgia treatment TNX-102 SL, highlighting two positive Phase 3 trials with NDA filing expected in H2 2024 and FDA approval anticipated in H2 2025. The company is a CNS-focused biopharma with marketed migraine therapies and a pipeline including a biologic cocaine antidote with FDA Breakthrough Therapy Designation.

Browse all conferences →

Related tags

Your message matters.

Let us design a presentation that delivers.

Lets get started

More from Tonix Pharmaceuticals Holding Corp.

View all →

Tonix Pharmaceuticals BIO 2024 Corporate Presentation

conference

23 Pages

Tonix Pharmaceuticals Corporate Presentation February 2017

investor_presentation

Similar conferences from other companies

Browse all →

IDEXX Laboratories 2017 Raymond James Institutional Investors Conference

conference

30 Pages

IDEXX Laboratories

Anika Therapeutics 2017 Canaccord Genuity Musculoskeletal Conference

conference